Myeloma Crowd Radio: Dr. Paul Shami, MD, Huntsman Cancer Institute

JSK is the first in its class with a new and unique method of killing multiple myeloma. It has a broad-spectrum anti-cancer activity, especially for myeloma and AML (acute myeloid leukemia) but is not toxic for normal cells. The JSK product is running through the standard approval process and is now in an advanced stage of pre-clinical development. Orphan drug designation has been obtained for myeloma and toxicology studies are now in the planning stages. JSK is active against drug-resistant myeloma cells and could be use with bortezomib to treat multiple myeloma. Dr. Paul Shami, MD of the Huntsman Cancer Institute joins us to describe the develoment and use of this new treatment now in development. Thanks to our episode sponsor, Takeda Oncology.